BioSpace News Archive

ViewRay, Inc. announced financial results for the fourth quarter and year ended December 31, 2020.

Soliton, Inc., a medical device company with a novel and proprietary platform technology, reported financial results for the fourth quarter and full year ended December 31, 2020.

DURECT Corporation announced financial results for the three months and year ended December 31, 2020 and provided a corporate update.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported financial results for the quarter and year ended December 31, 2020.

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported its financial results for the year ended December 31, 2020 and provided a business update.

Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET.

Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it has priced an offering of $400.0 million aggregate principal amount of 2.550% Senior Notes due 2031 at an issue price of 99.965% of the principal amount and $400.0 million aggregate principal amount of 3.625% Senior Notes due 2051 at an issue price of 99.999% of the principal amount.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $31.00 per share.

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Andrew Sinclair, Ph.D., to its board of directors.